MaxCyte To Be Featured Speaker At The 2nd Annual Stem Cell Summit

MaxCyte, Inc., a
clinical-stage therapeutic company and pioneer in large-scale, non-viral
cell loading systems, announces that Madhusudan V. Peshwa, PhD, Vice
President, Research and Development, will be a featured speaker at the 2nd
Annual Stem Cell Summit in San Diego, CA, on Monday, February 12, 2007 at
3:00 pm.



Dr. Peshwa's presentation will provide an overview of MaxCyte's
approach to customizing and augmenting biological activity of stem cell
products and their implementation, utilizing the company's proprietary
technology platform, into robust, scalable, cGMP-compliant manufacturing
processes for clinical and commercial delivery.



About MaxCyte



MaxCyte is a clinical-stage cell therapeutics company with a rapidly
growing pipeline of product development partnerships in cell-based
therapies. The Company's proprietary ex vivo cell loading technology
overcomes critical obstacles such as safety, scalability and
reproducibility which are fundamental to successful cell-based therapies.
MaxCyte has demonstrated the value of its versatile technology in partnered
therapeutic programs in oncology, pulmonary, metabolic and infectious
diseases as well as in development collaborations with leading researchers.
Current clinical programs with MaxCyte-engineered cells include a Phase
I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and
a Phase IIa study for the treatment of primary Pulmonary Arterial
Hypertension (PAH). In addition, there are advanced preclinical programs in
oncology and regenerative medicine. More than 16 commercial and academic
partners are currently using the MaxCyte technology. The MaxCyte system has
an FDA Master File in place at CBER.



For more information, visit maxcyte.



This press release may contain, in addition to historical information,
certain forward-looking statements that involve risks and uncertainties.
Such statements reflect management's current views and are based on certain
assumptions. Actual results could differ materially from those currently
anticipated as a result of a number of factors, including risks and
uncertainties.


MaxCyte, Inc.

maxcyte